394 related articles for article (PubMed ID: 8774881)
1. Receptor-associated Mad homologues synergize as effectors of the TGF-beta response.
Zhang Y; Feng X; We R; Derynck R
Nature; 1996 Sep; 383(6596):168-72. PubMed ID: 8774881
[TBL] [Abstract][Full Text] [Related]
2. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4.
Nakao A; Imamura T; Souchelnytskyi S; Kawabata M; Ishisaki A; Oeda E; Tamaki K; Hanai J; Heldin CH; Miyazono K; ten Dijke P
EMBO J; 1997 Sep; 16(17):5353-62. PubMed ID: 9311995
[TBL] [Abstract][Full Text] [Related]
3. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
4. Lack of transforming growth factor-beta type II receptor expression in human retinoblastoma cells.
Horie K; Yamashita H; Mogi A; Takenoshita S; Miyazono K
J Cell Physiol; 1998 Jun; 175(3):305-13. PubMed ID: 9572475
[TBL] [Abstract][Full Text] [Related]
5. Smad6 inhibits signalling by the TGF-beta superfamily.
Imamura T; Takase M; Nishihara A; Oeda E; Hanai J; Kawabata M; Miyazono K
Nature; 1997 Oct; 389(6651):622-6. PubMed ID: 9335505
[TBL] [Abstract][Full Text] [Related]
6. DPC4 (SMAD4) mediates transforming growth factor-beta1 (TGF-beta1) induced growth inhibition and transcriptional response in breast tumour cells.
de Winter JP; Roelen BA; ten Dijke P; van der Burg B; van den Eijnden-van Raaij AJ
Oncogene; 1997 Apr; 14(16):1891-9. PubMed ID: 9150356
[TBL] [Abstract][Full Text] [Related]
7. Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes.
Deacu E; Mori Y; Sato F; Yin J; Olaru A; Sterian A; Xu Y; Wang S; Schulmann K; Berki A; Kan T; Abraham JM; Meltzer SJ
Cancer Res; 2004 Nov; 64(21):7690-6. PubMed ID: 15520171
[TBL] [Abstract][Full Text] [Related]
8. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors.
Goumans MJ; Valdimarsdottir G; Itoh S; Rosendahl A; Sideras P; ten Dijke P
EMBO J; 2002 Apr; 21(7):1743-53. PubMed ID: 11927558
[TBL] [Abstract][Full Text] [Related]
9. Interaction between Smad anchor for receptor activation and Smad3 is not essential for TGF-beta/Smad3-mediated signaling.
Goto D; Nakajima H; Mori Y; Kurasawa K; Kitamura N; Iwamoto I
Biochem Biophys Res Commun; 2001 Mar; 281(5):1100-5. PubMed ID: 11243848
[TBL] [Abstract][Full Text] [Related]
10. A WD-domain protein that is associated with and phosphorylated by the type II TGF-beta receptor.
Chen RH; Miettinen PJ; Maruoka EM; Choy L; Derynck R
Nature; 1995 Oct; 377(6549):548-52. PubMed ID: 7566156
[TBL] [Abstract][Full Text] [Related]
11. TLP, a novel modulator of TGF-beta signaling, has opposite effects on Smad2- and Smad3-dependent signaling.
Felici A; Wurthner JU; Parks WT; Giam LR; Reiss M; Karpova TS; McNally JG; Roberts AB
EMBO J; 2003 Sep; 22(17):4465-77. PubMed ID: 12941698
[TBL] [Abstract][Full Text] [Related]
12. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.
Wang D; Kanuma T; Mizunuma H; Takama F; Ibuki Y; Wake N; Mogi A; Shitara Y; Takenoshita S
Cancer Res; 2000 Aug; 60(16):4507-12. PubMed ID: 10969799
[TBL] [Abstract][Full Text] [Related]
13. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.
DaCosta Byfield S; Major C; Laping NJ; Roberts AB
Mol Pharmacol; 2004 Mar; 65(3):744-52. PubMed ID: 14978253
[TBL] [Abstract][Full Text] [Related]
14. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition.
Peng SB; Yan L; Xia X; Watkins SA; Brooks HB; Beight D; Herron DK; Jones ML; Lampe JW; McMillen WT; Mort N; Sawyer JS; Yingling JM
Biochemistry; 2005 Feb; 44(7):2293-304. PubMed ID: 15709742
[TBL] [Abstract][Full Text] [Related]
15. Mad-related genes in the human.
Riggins GJ; Thiagalingam S; Rozenblum E; Weinstein CL; Kern SE; Hamilton SR; Willson JK; Markowitz SD; Kinzler KW; Vogelstein B
Nat Genet; 1996 Jul; 13(3):347-9. PubMed ID: 8673135
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of activation of the TGF-beta receptor.
Wrana JL; Attisano L; Wieser R; Ventura F; Massagué J
Nature; 1994 Aug; 370(6488):341-7. PubMed ID: 8047140
[TBL] [Abstract][Full Text] [Related]
17. A human Mad protein acting as a BMP-regulated transcriptional activator.
Liu F; Hata A; Baker JC; Doody J; Cárcamo J; Harland RM; Massagué J
Nature; 1996 Jun; 381(6583):620-3. PubMed ID: 8637600
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor-β signalling: role and consequences of Smad linker region phosphorylation.
Kamato D; Burch ML; Piva TJ; Rezaei HB; Rostam MA; Xu S; Zheng W; Little PJ; Osman N
Cell Signal; 2013 Oct; 25(10):2017-24. PubMed ID: 23770288
[TBL] [Abstract][Full Text] [Related]
19. The interaction between two TGF-beta type I receptors plays important roles in ligand binding, SMAD activation, and gradient formation.
Haerry TE
Mech Dev; 2010; 127(7-8):358-70. PubMed ID: 20381612
[TBL] [Abstract][Full Text] [Related]
20. Functional conservation of Schistosoma mansoni Smads in TGF-beta signaling.
Beall MJ; McGonigle S; Pearce EJ
Mol Biochem Parasitol; 2000 Nov; 111(1):131-42. PubMed ID: 11087923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
